COVID-19 is significantly milder now than it was during the first two years of the pandemic, for most people. By mid-2022, the death rate among hospitalized COVID patients had already dropped to about one-third of what it was during the Delta wave. That trend has continued, driven by a combination of widespread immunity, less dangerous variants, and the virus itself evolving to replicate more in the nose and less in the lungs.
But “milder on average” doesn’t mean mild for everyone. The virus still sends hundreds of thousands of people to the hospital each year, and certain groups remain at serious risk.
How Much Milder, Exactly?
The clearest data comes from CDC tracking of hospitalized patients. During the Delta wave (mid-2021), roughly 15 out of every 100 people hospitalized primarily for COVID died. By early 2022, when the first Omicron subvariants took over, that number fell to about 13 per 100. By spring 2022, it dropped again to 4.9 per 100, the lowest point recorded in the pandemic up to that time.
After adjusting for differences in patient age and health, the later Omicron period carried roughly one-quarter the mortality risk of the Delta period. That’s a dramatic reduction, and it happened before many of the subsequent Omicron offshoots that circulate today. The overall trajectory has continued downward since then, though seasonal surges still cause spikes in hospitalizations.
The Virus Itself Has Changed
Part of the improvement isn’t just immunity. The virus has genuinely become less dangerous to lung tissue. Research published in The Lancet found that newer Omicron subvariants consistently cause less damage in lung tissue compared to their predecessor strains, while actually replicating more efficiently in the upper airways (the nose and throat). This is a textbook pattern for respiratory viruses adapting to humans: they become better at spreading through the nose but worse at penetrating deep into the lungs, where the most life-threatening damage occurs.
This shift helps explain why current infections tend to feel more like a bad cold or flu for most people, with sore throat, congestion, fatigue, and cough dominating the symptom picture, rather than the severe pneumonia that characterized early pandemic waves.
Immunity Makes a Big Difference
The other major factor is that almost no one’s immune system is encountering this virus for the first time anymore. Most people have been vaccinated, infected, or both. This layered immunity doesn’t always prevent infection, but it dramatically reduces the chance that an infection will turn severe. The CDC identifies vaccination status as one of the key factors determining whether someone develops a serious case, alongside age and underlying health conditions.
This is also why the antiviral Paxlovid, while still useful for speeding recovery, no longer shows a clear benefit for preventing hospitalization or death in vaccinated, high-risk patients. In two large trials running from 2022 to 2024 involving over 4,200 participants, hospitalization and death rates were already so low in both the treatment and usual-care groups (under 1.2%) that the drug couldn’t improve on what immunity was already doing. Paxlovid recipients did recover faster, with one trial showing a median recovery time of 14 days versus 21 days without treatment.
Recovery Is Generally Faster
Current variants have a shorter incubation period than pre-Omicron strains. Symptoms typically begin three to six days after exposure and last up to 10 days for most people, though some experience lingering symptoms beyond that window. The acute, knock-you-flat phase that kept many early-pandemic patients in bed for two weeks or more is less common now, though it still happens.
Long COVID Risk Has Dropped, Not Disappeared
A pooled analysis of 35 studies across 19 countries found that the prevalence of long COVID dropped from 35.5% of infections in the pre-Omicron era to 22.8% during the Omicron period. That’s a meaningful reduction, but 22.8% is not a small number. Roughly one in four or five people infected during the Omicron era reported persistent symptoms. Factors like repeated infections, lack of vaccination, and pre-existing health conditions all appear to influence individual risk.
Who Still Faces Serious Risk
Age remains the single strongest predictor of a bad outcome. During the October 2023 to August 2024 surveillance period, 70% of COVID-associated hospitalizations were among adults 65 and older. Death rates were highest in people 75 and up. Older adults are less likely to have robust infection-acquired immunity and tend to mount weaker responses to vaccination due to natural age-related immune changes.
People with weakened immune systems are also disproportionately affected. Although only about 6% of the U.S. population has an immunocompromising condition, this group accounted for 16% of COVID hospitalizations between July 2023 and May 2024. For these individuals, the virus hasn’t become nearly as manageable as it has for the general population.
Home Tests Still Work, With Caveats
Rapid antigen tests detect current variants, but they may have reduced sensitivity compared to earlier strains. They’re also less likely to catch very early infections before the virus has had time to build up in the nose. If you test negative but still feel sick, the FDA recommends testing again a day or two later. A single negative rapid test doesn’t rule out COVID, especially in the first day or two of symptoms.
The Bottom Line on Severity
For a healthy, previously vaccinated or infected adult, a COVID infection in 2025 is far less likely to be dangerous than one in 2020 or 2021. The virus causes less lung damage, the population has broad immunity, and severe outcomes have fallen sharply. But the virus hasn’t become harmless. It still kills tens of thousands of Americans annually, disproportionately among older adults and people with compromised immune systems. “Milder” is accurate as a population-level statement. It’s just not a guarantee for any individual infection.